Valte Seq, a Gaithersburg MD-based biotechnology company focused on the genetic elucidation of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, raised $10M in Seed funding.
The round was led by Dongkoo Bio&Pharma Co. Ltd. with participation from OV Principal Investments.
The company intends to use the funds to accelerate the development of its HiF-Seq platform.
Co-founded in 2019 by Ted Dawson, Valina Dawson and D&D Pharmatech and led by Nina Urban, CEO, Valted Seq is focused on the discovery of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advanced therapeutics. Using its HiF-Seq platform, the company has created a large repository of transcriptomic data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimer’s and Parkinson’s.
It is also developing minimally invasive assays for:
- Detecting poly (ADP-ribose) (PAR) in cerebral spinal fluid (CSF), serum and serum-derived exosomes for diagnosis of Parkinson’s disease
- Diagnosing Parkinson’s and related α-synucleinopathies through assessment of c-Abl pathway molecules from CSF, serum, or serum-derived exosomes
These proprietary assays are highly specific for their target and have the potential to be used during clinical trials to inform target engagement, patient selection and become companion diagnostic assays.
FinSMEs
02/11/2021